GLP-1 RAs and Cardiovascular and Kidney Outcomes by Body Mass Index in Type 2 Diabetes
Authors' conclusion
In this cohort study of patients with type 2 diabetes, GLP-1 RAs use was associated with BMI-dependent cardiovascular benefits and consistent kidney protection, suggesting the importance of BMI stratification in guiding treatment decisions.
Study context
- Population
- Patients with T2D who received GLP-1 RAs or DPP-4i between 2011 and 2022, Chang Gung Research Database, multiple hospitals in Taiwan; mean (SD) age 57.4 (14.2) years
- Participants
- 7,200 matched patients
- Exposure
- GLP-1 RA vs DPP-4i initiation
- Outcome
- Major adverse cardiovascular events (MACE) (cardiovascular death, MI, ischemic stroke or hospitalization for HF) and composite kidney outcomes (eGFR decline ≥50% or progression to dialysis)
Methodological detailsmulticentre, propensity-score matched within body mass index (BMI) categories <25 and ≥25
- Multicentre
- Propensity-score matched within BMI categories <25 and ≥25
Main finding
As reported in the abstract
GLP-1 RAs vs DPP-4 inhibitorsEstimate (95% CI)
Cardiovascular death, BMI ≥25
HR 0.62(0.46–0.83)
Hospitalization for HF, BMI ≥25
subdistribution HR 0.77(0.62–0.94)
Observational data: associations, not effects.
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
GLP-1 RAs and Cardiovascular and Kidney Outcomes by Body Mass Index in Type 2 Diabetes. JAMA Netw Open. Published 2 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →